Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Baxter
Medtronic
Johnson and Johnson
Mallinckrodt

Last Updated: November 30, 2022

Obinutuzumab - Biologic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Recent Clinical Trials for obinutuzumab

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Loxo Oncology, Inc.Phase 2
The Leukemia and Lymphoma SocietyPhase 2
Gruppo Italiano Malattie EMatologiche dell'AdultoPhase 2

See all obinutuzumab clinical trials

Recent Litigation for obinutuzumab

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Acerta Pharma B.V. v. MSN Pharmaceuticals Inc.2022-02-03
Acerta Pharma B.V. v. Sandoz Inc.2022-02-03
Acerta Pharma B.V. v. Cipla Limited2022-02-03

See all obinutuzumab litigation

Pharmacology for obinutuzumab
Mechanism of ActionCD20-directed Antibody Interactions
Established Pharmacologic ClassCD20-directed Cytolytic Antibody
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for obinutuzumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for obinutuzumab Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for obinutuzumab Derived from Patent Text Search

No patents found based on company disclosures

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Baxter
AstraZeneca
Medtronic
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.